Simulations Plus, Inc. which can be found using ticker (SLP) have now 4 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 70 and 44 calculating the average target price we see $58.75. Given that the stocks previous close was at $42.82 and the analysts are correct then there would likely be a percentage uptick in value of 37.2%. The 50 day MA is $41.25 and the 200 day MA is $46.63. The total market capitalization for the company now stands at $863m. You can visit the company’s website by visiting: https://www.simulations-plus.com
The potential market cap would be $1,184m based on the market consensus.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.
The company has a dividend yield of 0.56% with the ex dividend date set at 21-4-2023 (DMY).
Other points of data to note are a P/E ratio of 86.28, revenue per share of 2.69 and a 3.68% return on assets.
